Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

Recruiting now · Phase 4

Conditions studied: Blunt Cerebrovascular Injury

In brief

The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.

Key facts

Study ID: NCT05868525
Run by: Loma Linda University
People needed: 98
Starts: 2023-08-23
Expected to finish: 2026-12-01
Last updated by the study team: 2026-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥18
All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission

You may not qualify if…

Age <18
Pregnant women
No enteral route access for Aspirin administration
Patients who are on Heparin drip or other full dose anticoagulation when BCVI diagnosed
Patients who are on other Anti-Platelets aside from Aspirin when BCVI diagnosed
Patients with BCVI grade 5 injury based on Biffl classification
Presence of any contraindication or history of allergy to Aspirin
Patient with the diagnosis of acute stroke at the time of BCVI diagnosis matching the injured vessel territory on imaging
Patients with acute spinal trauma that needs surgical intervention

Where it is running

Loma Linda University Medical Center — Loma Linda, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.